CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Returned to the company · Stock Option (Right to Buy) | −80,000 | 0 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Returned to the company · Stock Option (Right to Buy) | −13,333 | 0 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +13,333 | 13,333 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Returned to the company · Stock Option (Right to Buy) | −65,000 | 0 | ||
| 2025-09-01 | Cappello Joseph Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2025-08-27 | Tyree James L Director | Grant or award | +22,283 | 68,074 | ||
| 2025-08-27 | Tyree James L Director | Grant or award · Stock Option (Right to Buy) | +28,576 | 28,576 | ||
| 2025-08-27 | Smither John W Director | Grant or award | +22,283 | 74,994 | ||
| 2025-08-27 | Smither John W Director | Grant or award · Stock Option (Right to Buy) | +28,576 | 28,576 | ||
| 2025-08-27 | Mirabelli Mary Director | Grant or award | +22,283 | 73,284 | ||
| 2025-08-27 | Mirabelli Mary Director | Grant or award · Stock Option (Right to Buy) | +28,576 | 28,576 | ||
| 2025-08-27 | Thomas John Director | Grant or award | +22,283 | 502,784 | ||
| 2025-08-27 | Thomas John Director | Grant or award · Stock Option (Right to Buy) | +28,576 | 28,576 | ||
| 2025-08-27 | Zindrick Thomas President and CEO | Grant or award | +361,200 | 554,161 | ||
| 2025-08-27 | Zindrick Thomas President and CEO | Grant or award · Stock Option (Right to Buy) | +478,800 | 478,800 | ||
| 2025-08-27 | Yu Yong SVP, Clinical Development | Grant or award | +101,480 | 150,036 | ||
| 2025-08-27 | Yu Yong SVP, Clinical Development | Grant or award · Stock Option (Right to Buy) | +134,520 | 134,520 | ||
| 2025-08-27 | Smalling Ralph Head of Regulatory | Grant or award | +26,230 | 60,990 | ||
| 2025-08-27 | Smalling Ralph Head of Regulatory | Grant or award · Stock Option (Right to Buy) | +34,770 | 34,770 |
Page 4 of 9 · 170 trades